// App-Quantinova.ai

3017 : Biomarker characterization using mass cytometry in a phase 1 trial of urelumab (BMS-663513) in subjects with advanced solid tumors and relapsed/refractory B-cell non-Hodgkin lymphoma.

Researchers

Presenter

  • Cariad Chester

Principal Investigators

  • Serena Chang

  • John F. Kurland

  • Maria Jure-Kunkel

  • Holden Maecker

  • Ronald Levy

  • Amanda Rajapaksa

  • Erin Waller

  • Mohith Sadaram

  • Lori Richards

  • Lewis J. Cohen

  • Christoph Matthias Ahlers

Medical Centers

  • Department of Medicine, Division of Oncology, Stanford University, Stanford, CA

  • Institute for Immunity, Transplantation and Infection, Stanford School of Medicine, Stanford, CABristol-Myers Squibb, Princeton, NJ

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • B-Cell Non-Hodgkin Lymphoma

  • Solid malignancies

  • Non-Hodgkin's Lymphoma

  • Non‐Hodgkin Lymphoma

  • Hodgkin's Lymphoma

  • Lymphomas

Biomarkers

  • Peripheral blood mononuclear cell

Drug/Treatment

  • BMS-663513

  • lonomycin

  • Urelumab

Outcome

  • Positive

Study Design

  • N/A

Phase

  • I

Study Id's

  • NCT01471210

Sponsors

  • Bristol-Myer Squibb

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved